Ref: Syn/CS/SE/BM/2022-23/April/11

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

April 27, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Subject: Allotment of Shares under Syngene Restricted Stock Unit Long Term Incentive Plan FY 2020.

Ref: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 10(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014

Dear Sir/Madam,

We hereby inform that the Board of Directors of the Company at its meeting held today i.e. April 27, 2022, has allotted 6,38,000 equity shares to the Syngene Employee Welfare Trust under the Syngene Restricted Stock Unit Long Term Incentive Plan FY 2020.

Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs. 4,00,79,65,000/- (40,07,96,500 Equity Shares of Rs. 10/- each) to Rs. 401,43,45,000 /- (40,14,34,500 Equity Shares of Rs. 10/- each).

In terms of Regulation 10(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014 the details of shares allotted as above are given in Annexure A.

The above-mentioned information will also be available under "Investors" section of company's website at www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,
Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

PRIYADARSHINI MAHAPATRA

Digitally signed by PRIYADARSHINI MAHAPATRA
DN: c=IN, o=Personal, pseudonym=bc2eb3d598e4b4695dfab584d8c4954317f2c9b276b0ead69f4b6de415c5150d, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef26229a00b5f723a1ef57ab0005, postalCode=751015, st=ODISHA, serialNumber=df67e39aa5435d22f718c22d0516d97afb1208536f4ff1860285e06c72d0c9992, cn=PRIYADARSHINI MAHAPATRA
Date: 2022.04.27 15:25:49 +05'30'

Priyadarshini Mahapatra
Company Secretary & Compliance Officer

Syngene

Annexure -A

Disclosure pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits) Regulations, 2014.

Sl. No.	Particulars	Details
1.	Company name and address of Registered Office:	Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India.
2.	Name of the Stock Exchanges on which the company's shares are listed:	• National Stock Exchange of India Limited • BSE Limited
3.	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2014 with Stock Exchange:	BSE Filing Date: April 27, 2020 BSE Approval Date: May 07,2020 NSE Filing Date: April 27, 2020 NSE Approval Date: May 11,2020
4.	Filing Number, if any:	BSE: 108758 NSE: 23743
5.	Title of the Scheme pursuant to which shares are issued, if any:	Syngene Restricted Stock Unit Long Term Incentive Plan FY 2020.
6.	Kind of security to be listed:	Equity Shares
7.	Par value of the shares:	Rs. 10/- per share
8.	Date of issue of shares:	April 27, 2022 (allotment date)
9.	Number of shares issued:	6,38,000 equity shares
10.	Share Certificate No., if applicable:	Not applicable
11.	Distinctive number of the share, if applicable	40,07,96,501 to 40,14,34,500
12.	ISIN Number of the shares if issued in Demat :	INE398R01022
13.	Exercise price per share:	Rs. 10/- per share
14.	Premium per share:	Nil
15.	Total Issued shares after this issue:	40,14,34,500
16.	Total Issued share capital after this issue:	Rs. 4,01,43,45,000
17.	Details of any lock-in on the shares:	Not applicable
18.	Date of expiry of lock-in:	Not applicable
19.	Whether shares identical in all respects to existing shares if not, when will they become identical?:	All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
20.	Details of listing fees, if payable:	Paid